NEW HAVEN, Conn., April 5, 2018 /PRNewswire/ -- Kleo
Pharmaceuticals, a biopharmaceutical company developing innovative
small molecule immunotherapies, announced today that CEO
Doug Manion, M.D. FRCP (C) will be
presenting at Biotech Innovations Conference in New York, NY on
Monday, April 9th from 1:30-2:00PM. Bloomberg
Intelligence and Mass Innovation Labs are co-hosting the event
focusing on the exciting and evolving landscape of the biotech
industry and will feature company presentations that focus on
private and recently public biotech firms who are pioneers in
immuno-oncology, cell therapy, and gene therapy fields.
A live webcast and replay will be available on the Bloomberg
Terminal on the LIVE<Go> function for subscribers. Kleo will
provide access to a video of the presentation on its website when
it becomes available.
About Kleo Pharmaceuticals Inc.
Kleo Pharmaceuticals
Inc. is a biopharmaceutical company founded to develop and advance
the pioneering technology that originated in the laboratory of
co-founder David Spiegel, M.D.,
Ph.D. at Yale University. Initially
funded by Biohaven Pharmaceuticals Holding Ltd (NYSE: BHVN) and
Connecticut Innovations, Kleo is focused on developing small
molecule-based immunotherapies that emulate biologics. Our 2 novel
platforms—Antibody Recruiting Molecules (ARMs™) and Synthetic
Antibody Mimics (SyAMs™)— are designed to direct a patient's immune
system to fight specific disease-causing cells. For more
information, please visit: www.kleopharmaceuticals.com.
CONTACT INFORMATION
Contact:
Roy
Prieb
Kleo Pharmaceuticals Inc.
203-691-6961 ext. 202
email: pr@kleopharmaceuticals.com
website: www.kleopharmaceuticals.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/kleo-pharmaceuticals-selected-to-present-at-biotech-innovation-conference-300625038.html
SOURCE Kleo Pharmaceuticals Inc.